DS-3939a
DS-3939a (DS-3939) is an anti-TA-MUC1 (tumor-associated mucin-1) antibody-drug conjugate (ADC) . DS-3939a consists of a humanized anti-TA-MUC1 IgG1 monoclonal antibody Gatipotuzumab (HY-P99634), a stable and cleavable tetrapeptide-based linker (Gly-Gly-Phe-Gly), and a DNA topoisomerase I inhibitor payload (DXd) (HY-13631D), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) . DS-3939a inhibits the growth of TA-MUC1-positive cancer cells (CFPAC-1, NCI-H2110) by inducing DNA damage and apoptosis. DS-3939a exhibits significant antitumor activity in a variety of TA-MUC1-expressing advanced solid tumors. DS-3939a can be used for the study of TA-MUC1-expressing advanced cancers[1].
Product Specifications
Product Name Alternative
DS-3939
UNSPSC
12352005
Target
Antibody-Drug Conjugates (ADCs) ; Apoptosis; Mucin; Topoisomerase
Related Pathways
Antibody-drug Conjugate/ADC Related; Apoptosis; Cell Cycle/DNA Damage; Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Purity
96.03
Smiles
[DS-3939a]
References & Citations
[1]Takano K, et al. DS-3939a: A TA-MUC1-directed Antibody-Drug Conjugate with Broad Anti-Tumor Activity. Mol Cancer Ther. 2025 Jul 10.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C, protect from light
Scientific Category
ADC Related
Clinical Information
No Development Reported
Isoform
MUC1; Topo I
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
